SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-21-023504
Filing Date
2021-10-12
Accepted
2021-10-12 07:04:00
Documents
13
Period of Report
2021-10-11
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20211011_8k.htm   iXBRL 8-K 27717
  Complete submission text file 0001437749-21-023504.txt   164074

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA dffn-20211011.xsd EX-101.SCH 3594
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dffn-20211011_def.xml EX-101.DEF 11808
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dffn-20211011_lab.xml EX-101.LAB 15859
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dffn-20211011_pre.xml EX-101.PRE 12023
6 EXTRACTED XBRL INSTANCE DOCUMENT dffn20211011_8k_htm.xml XML 2662
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 211316858
SIC: 2834 Pharmaceutical Preparations